<DOC>
	<DOCNO>NCT01964144</DOCNO>
	<brief_summary>There effective treatment advance thyroid cancer amenable surgery concentrate iodine . Response rate chemotherapy low best supportive care standard care patient . In recent phase I phase II clinical study , dovitinib show activity single agent solid tumor . Therefore , conduct phase II , single-arm trial determine efficacy dovitinib radioactive iodine-refractory recurrent metastatic thyroid cancer .</brief_summary>
	<brief_title>An Open-label , Multicenter , Phase II Study Dovitinib Advanced Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Histologically proven diagnosis thyroid cancer ( papillary , follicular/Hürthle cell variant , medullary ) Patients metastatic unresectable thyroid cancer curative measure ( surgical resection , externalbeam radiation therapy , radioactive iodine ) longer effective Documented evidence disease progression ( base radiographic image ) , accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , within 6 month entry study papillary follicular/Hürthle cell variant Prior therapy surgery , 131I treatment , chemotherapy , radiotherapy allow , within 3 week treatment . Patients receive prior biologic treatment ( kinase inhibitor , vaccine antibodybased therapy ) , except prior VEGFR/FGFR inhibitor therapy , allow 3 week treatment . Patients must least one measurable lesion , externally irradiate , define RECIST criterion version 1.1 Age : 2090 Performance status Eastern Cooperative Oncology Group 0 2 Life expectancy &gt; 3 month Adequate bone marrow function : ANC≥1,500/uL , hemoglobin≥9.0 g/dL ( correct transfusion ) platelet≥100,000/uL Adequate renal function ( creatinine &lt; 1.5 mg/dL ) Adequate liver function ( total bilirubin &lt; 1.5 x ULN , transaminase &lt; 3 x ULN ) Adequate blood glucose lipid level ( fast cholesterol &lt; 2xUNL , triglyceride &lt; 2xUNL , HbA1c &lt; 9 % ) Patient compliance geographic proximity allow adequate follow Patients CNS metastases Patients another primary malignancy within 3 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , skin cancer ( basal cell carcinoma , squamous cell carcinoma , nonmelanomatous skin cancer ) Patients receive last administration anticancer therapy include chemotherapy , immunotherapy , hormonal therapy monoclonal antibody ( exclude nitrosurea , mitomycinC , target therapy radiation ) ≤ 4 week prior start study drug , recover side effect therapy Patients receive last administration nitrosurea mitomycinC ≤ 6 week prior start study drug , recover side effect therapy Patients receive targeted therapy ( e.g . sunitinib , sorafenib , pazopanib ) ≤ 2 week prior start study drug , recover side effect therapy Patients radiotherapy ≤ 4 week prior start study drug , ≤ 2 week prior start study drug case localize radiotherapy ( e.g . analgesic purpose lytic lesion risk fracture ) , recover radiotherapy toxicity Pregnant breastfeed woman Fertile male willing use contraception , state Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>thyroid cancer , dovitinib</keyword>
</DOC>